HAROLD D. ROSE, M.D.; DONALD A. ROTH, M.D., PH.D.; JOSEPH J. BARBORIAK, SC.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Miconazole is an antifungal agent administered intravenously for the treatment of systemic infections. The drug is solubilized in aqueous solution by the use of polyethoxylated castor oil; this solubilizer has been reported to cause lipid abnormalities, including hyperlipedemia in humans and rats (1). The quantitative composition of the ethoxylated castor oil and the metabolic fate of several of its components are unknown.
We have observed serum lipid changes in two patients undergoing treatment with maximum doses of 1.5 to 3 g of miconazole/d for 6 weeks. The volume infused in both patients was 150 to 300 mL/d,
ROSE HD, ROTH DA, BARBORIAK JJ. Hyperlipidemia Related to Miconazole Therapy. Ann Intern Med. 1979;91:491–492. doi: https://doi.org/10.7326/0003-4819-91-3-491_2
Download citation file:
Published: Ann Intern Med. 1979;91(3):491-492.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use